Vall d'Hebron
Search

Home > Research Programs > Molecular Pathology Group

More groups

Molecular Pathology Group

Strategic Goals

  1. To serve as translator between basic and clinical research
  2. Molecular pathology strategies serving clinical oncology needs
  3. Discovery of biomarkers
  4. Participate as central and local laboratory in clinical trials performing  pharmacodynamic studies

Current objectives

  • Preclinical animal models exploring novel Akt/mTOR inhibitors as well as new therapeutic combinations such as PI3K/Akt/mTOR inhibitors with MEK inhibitors or mTOR inhibitors with anti-IGF-IR agents.
  • Generate a DNA extraction platform from archival tissue in order to perform high through-put gene sequencing, profiling tumoral samples from diverse sources.

Team

Santiago Ramón y Cajal

Principal Investigator

Attending Physicians

  • Claudia Aura MD
  • Ludmila Prudkin MD
  • Stefania Landolfi MD
  • Carmela Iglesias MD
  • Josep Castellví MD

Laboratory Supervisor

  • José Jiménez

Technicians

  • Sonia Rodríguez
  • Elisabeth Llonch
  • Nerea Peiró
  • Gertrudis Sánchez

Assistant

  • Mª Angeles Díaz

NEO-ALTTO Central Lab Coordinator

  • Laurence Lebreton

Publications

  • Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, Baselga J, Arribas J. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 2009 Jun; 29(12): 3319-31
  • Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramón y Cajal S, Arribas J, Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009 Feb; 28(6): 803-14
  • Monge M, Doll A, Colas E, Gil-Moreno A, Castellví J, Garcia A, Colomé N, Perez-Benavente A, Pedrola N, Lopez-Lopez R, Dolcet X, Ramón y Cajal S, Xercavins J, Matias-Guiu X, Canals F, Reventos J, Abal M. Subtractive proteomic approach to the endometrial carcinoma invasion front. J. Proteome Res. 2009 Oct; 8(10): 4676-84
  • Benavente S, Verges R, Hermosilla E, Fumanal V, Casanova N, Garcia A, Ramón y Cajal S, Giralt J. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009 Dec; 75(5): 1316-22
  • Bielanska J, Hernandez-Losa J, Pérez-Verdaguer M, Moliné T, Somoza R, Ramón y Cajal S, Condom E, Ferreres JC, Felipe A. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets 2009 Dec; 9(8): 904-14

All publications